Alberto Savrieno
Contributor since: 2012
Alimera Vs. pSivida, A Comprehensive Comparison
Excess Reserves: The Elephant In The Room The Fed Doesn't Want To Talk About
China On The Verge Of Deflationary Crash: Primary And Secondary Plays
Is A Patent War About To Erupt Between Evolva And Stevia First?
Cervical Cancer Should Not Be Ignored By Biotech Investors
Cyber Security The Next Big Thing In Internet Stocks; Lessons From The Tech Bubble
Market Running On Fumes, Prepare Your Exit Strategy
Athersys Has Some Promise, But Controversy And Doubt Remain
Pandora, Groupon, Zynga And Mobivity: Hard Numbers Show They're Turning A Corner
The Bottom Is In For Gold And Mining Stocks
New Developments In Ophthalmology Indicate Likely Surprises
Some Lesser Known Healthcare Prospects For 2013
Technology Revolution To Shape EV Charging Landscape
Pershing Gold Is A Good Guy And Great Buy, But Not For The Reasons You Think
Gold Stocks Are A Minefield, Pun Intended
How To Invest In Patent Holding Companies
Catching The Tail End Of Nutritional Supplements' Massive 3 Year Run
The Fed's Powder Keg Is Locked And Loaded - Gold Armor Is The Best Defense
Not Enough Cash For Sunshine Heart
Pfizer, Novartis And Northwest Biotherapeutics In A Race For IVF Inspired Cancer Cure
What Does The U.S. Trade Deficit Have To Do With Chinese Education?
An Acquisition Opportunity For Small Players With The Right Stuff
Opko, Bristol-Myers, Teva And A Frosty Debate In The Mix
Hooters Vs. McDonald's, Chanticleer's Fast Food American Dream
The Hidden Value In Electric Vehicle Infrastructure
The Israel Discount - An Opportunity To Pick Up Teva, Prolor Cheap
Colony Collapse Disorder As Part Of An Acquisition Strategy